NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SION

Sionna Therapeutics Inc

Jun 30 • 04:00PM ET

17.35

Dollar change +1.51
Percentage change 9.53	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWO SCHA IWC SCHB RSSL BBC AVUS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	46.56%	Shs Outstand	44.09M	Perf Week	23.05%
Market Cap	765.56M	Forward P/E	-	EPS next Y	-2.87	Insider Trans	20.32%	Shs Float	23.58M	Perf Month	22.96%
Enterprise Value	505.39M	PEG	-	EPS next Q	-0.56	Inst Own	54.07%	Short Float	11.99%	Perf Quarter	50.09%
Income	-	P/S	-	EPS this Y	83.43%	Inst Trans	39.33%	Short Ratio	15.68	Perf Half Y	-
Sales	-	P/B	2.17	EPS next Y	-8.40%	ROA	-	Short Interest	2.83M	Perf YTD	-30.60%
Book/sh	7.98	P/C	2.84	EPS next 5Y	40.90%	ROE	-	52W High	25.19 -31.12%	Perf Year	-
Cash/sh	6.11	P/FCF	-	EPS past 3/5Y	-23.81% -	ROIC	-	52W Low	7.26 139.15%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.00% 9.86%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	28.73	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.68	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	28.73	EPS Q/Q	-	SMA20	10.74%	Beta	-	Target Price	38.50
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	24.40%	Rel Volume	1.34	Prev Close	15.84
Employees	41	LT Debt/Eq	0.02	Earnings	May 12 BMO	SMA200	21.39%	Avg Volume	180.37K	Price	17.35
IPO	Feb 07, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-38.55% -	Trades		Volume	239,908	Change	9.53%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Initiated	TD Cowen	Buy
Mar-04-25	Initiated	Stifel	Buy	$32
Mar-04-25	Initiated	Guggenheim	Buy	$45

Jun-06-25 11:00AM	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model (GlobeNewswire) +7.42%
Jun-04-25 01:54PM	Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial (Benzinga) +9.12%
07:00AM	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis (GlobeNewswire)
Jun-03-25 07:00AM	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 07:00AM	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference (GlobeNewswire)
07:00AM	Loading…
May-12-25 07:00AM	Sionna Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-30-25 07:00AM	Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 (GlobeNewswire)
Mar-20-25 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-15-25 04:43PM	Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:25AM	Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey) -5.04%
Mar-03-25 12:57PM	Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-25-25 05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology) -13.37%
Feb-24-25 08:00AM	Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
07:51PM	Loading…
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	10% Owner	Feb 10 '25	Buy	18.00	1,125,000	20,250,000	6,684,962	Feb 12 05:21 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 10 '25	Buy	18.00	1,125,000	20,250,000	6,923,365	Feb 10 05:04 PM
ORBIMED ADVISORS LLC	Director	Feb 10 '25	Buy	18.00	550,000	9,900,000	3,704,959	Feb 10 04:28 PM
Thompson Peter A.	Director	Feb 10 '25	Buy	18.00	550,000	9,900,000	3,704,959	Feb 10 04:05 PM
Booth Bruce	Director	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SION

Sionna Therapeutics Inc

Upgrade your FINVIZ experience